Based on animal research and "in vitro" research with human proteins, bupropion has been characterized as a weak norepinephrine-dopamine reuptake inhibitor (NDRI), and has also been found to act as a releasing agent of dopamine and norepinephrine (NDRA).
It has also been found to act as a releasing agent of dopamine and norepinephrine (NDRA). Based on animal and human proteins research, bupropion has been characterized as a weak norepinephrine-dopamine reuptake inhibitor (NDRI).
Based on animal and human proteins research, bupropion has been characterized as a weak norepinephrine-dopamine reuptake inhibitor (NDRI). It has also been found to act as a releasing agent of dopamine and norepinephrine (NDRA).
Based on animal and human proteins research, bupropion has been characterized as a weak norepinephrine-dopamine reuptake inhibitor (NDRI). It has also been found to act as a releasing agent of dopamine and norepinephrine (NDRA).